Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: The GOLDN study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 6, 2007, Pages 1417-1425

  Lai, Chao Qiang ^a   Arnett, Donna K ^b   Corella, Dolores ^c   Straka, Robert J ^d   Tsai, Michael Y ^e   Peacock, James M ^f   Adiconis, Xian ^a   Parnell, Laurence D ^a   Hixson, James E ^g   Province, Michael A ^h   Ordovas, Jose M ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APOA5; Fenofibrate; Gene drug interaction; Increasing HDL C; Triglyceride lowering

Indexed keywords

APOLIPOPROTEIN A5; FAT; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN VARIANT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; APOLIPOPROTEINS A; AREA UNDER CURVE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYTOSINE; DIETARY FATS; FEMALE; GENE FREQUENCY; GENOTYPE; GUANINE; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; MALE; MIDDLE AGED; PARTICLE SIZE; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTPRANDIAL PERIOD; PROCETOFEN; THYMINE; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 34249294501     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.140103     Document Type: Article

References (36)

1. Fruchart JC, Nierman MC, Stroes ESG, Kastelein JJP, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109:(Suppl. III) III-15-III-19.
2. Szapary PO, Rader D. The triglyceride-high-density lipoprotein axis:an important target of therapy? Am Heart J. 2004;148:211-221.
3. Zilversmit DB. Atherogenesis:a postprandial phenomenon. Circulation. 1979;60:473-485.
4. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med. 1999;246:341-355.
5. Gianturco SH, Lin AH, Hwang SL, Young J, Brown SA, Via DP, Bradley WA. Distinct murine macrophage receptor pathway for human triglyceride-rich lipoproteins. J Clin Invest. 1988;82:1633-1643.
6. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol. 2000;11:615-620.
7. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088-93.
8. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferators activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907-925.
9. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther. 2006;11(3):211-21.
10. Brisson D, Ledoux K, Bosse Y, St-Pierre J, Julien P, Perron P, Hudson TJ, Vohl MC, Gaudet D. Effect of apolipoprotein E, peroxisome proliferator- activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics. 2002;12(4):313-20.
11. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, and Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294:169-173.
12. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low. Clin Chem. 2005;51(2):351-9.
13. Ishihara M, Kujiraoka T, Iwasaki T, Nagano M, Takano M, Ishii J, Tsuji M, Ide H, Miller IP, Miller NE, Hattori H. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res. 2005;46(9):2015-22.
14. Lai CQ, Demissie S, Cupples LA, Zhu Y, Adiconis X, Parnell LD, Corella D, Ordovas JM. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res. 2004;45:2096-2105.
15. Talmud PJ, Palmen J, Putt W, Lins L, Humphries SE. Determination of the functionality of common APOA5 polymorphisms. J Biol Chem. 2005;280(31):28215-20.
16. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, and Cohen JC. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet. 2002;11(24):3031-3038.
17. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, and Humphries SE. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002;11(24):3039-3046.
18. Nabika T, Nasreen S, Kobayashi S, and Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis. 2002;165:201-204.
19. Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, Adiconis X, Ordovas JM. The apolipoprotein A5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res. 2003;44:2365-2373.
20. Ribalta J, Figuera L, Fernandez-Ballart J, Vilella E, Castro Cabezas M, Masana L, Joven J. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem. 2002;48:1597-1600.
21. Jang Y, Kim JY, Kim OY, Lee JE, Cho H, Ordovas JM, Lee JH. The -1131T->C polymorphism in the apolipoprotein A5 gene is associated with postprandial hypertriacylglycerolemia;elevated small, dense LDL concentrations;and oxidative stress in nonobese Korean men. Am J Clin Nutr. 2004;80(4):832-840.
22. Martin S, Nicaud V, Humphries SE, Talmud PJ. EARS group. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta. 2003;1637:217-225.
23. Hsu LA, Ko YL, Chang CJ, Hu CF, Wu S, Teng MS, Wang CL, Ho WJ, Ko YS, Hsu TS, Lee YS. Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis. 2006;185:143-149.
24. Yan SK, Cheng XQ, Song YH, Xiao XH, Bi N, and Chen BS. Apolipoprotein A5 gene polymorphism -1131T>C:association with plasma lipids and type 2 diabetes mellitus with coronary heart disease in Chinese. Clin Chem Lab Med. 2005;43(6):607-612.
25. Lai CQ, Corella D, Demissie S, Cupples LA, Adiconis X, Zhu Y, Parnell LD, Tucker KL, Ordovas JM. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study. Circulation. 2006;113:2062-2070.
26. Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge' E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, Fruchart JC. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor α activators. J Biol Chem. 2003;278:17982-17985.
27. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 48(3-4):171-180, 2002.
28. Tsai MY, Georgopoulos A, Otvos JD, Ordovas JM, Hanson NQ, Peacock JM, Arnett DK. Comparison of ultracentrifugation and nuclear magnetic resonance spectroscopy in the quantification of triglyceride-rich lipoproteins after an oral fat load. Clin Chem. 2004;50(7):1201-1204.
29. Livak KJ. 1999. Allelic discrimination using fluorogenic probes and the 5 nuclease assay. Genet Anal. 14;143-9.
30. Littell RC, Milliken GA, Stroup WW, and Wolfinger RD 1996. SAS System for Mixed Models. Cary, NC, SAS Institute, Inc.
31. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educational and Behavioral Stat. 1998;24:323-355.
32. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem. 2005;280(22):21553-60.
33. Vaessen SF, Schaap FG, Kuivenhoven JA, Groen AK, Hutten BA, Boekholdt SM, Hattori H, Sandhu MS, Bingham SA, Luben R, Palmen JA, Wareham NJ, Humphries SE, Kastelein JJ, Talmud PJ, Khaw KT. Apolipoprotein A-V, triglycerides and risk of coronary artery disease:the prospective Epic-Norfolk Population Study. J Lipid Res. 2006;47(9):2064-70.
34. Merkel M, Heeren J. Give me A5 for lipoprotein hydrolysis! J Clin Invest. 2005;115(10):2694-6.
35. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113(12):1556-63.
36. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995;96:2601-2605.